Chester County News and Community Website
WASHINGTON, D.C. — The Department of Veterans Affairs is launching a clinical trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder, expanding federal research into …
VA Launches MDMA Trial for PTSD, Alcohol Use Disorders Read More
WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) reported new late-stage clinical data showing strong patient response rates for its experimental QTORIN rapamycin treatment in rare vascular malformations, positioning the company …
Palvella Reports Late-Stage Success for Rare Disease Drug Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported that enrollment in its pivotal Phase 3 Alzheimer’s disease trial has reached 85% and remains on track for completion this summer, …
Annovis Nears Full AD Enrollment Ahead of NDA Plans Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) presented new Phase 2 data showing statistically significant reductions in lesion bleeding among patients treated with QTORIN rapamycin for cutaneous venous malformations, …
Palvella Advances Rare Disease Program With Phase 2 Data Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) recently dosed the first patients in a Phase 2 study evaluating QTORIN rapamycin gel for angiokeratomas, a rare vascular-related skin disorder with no …
Palvella Doses First Patients in Rare Disease Skin Trial Read More
WAYNE, PA — A peer-reviewed study of Cagent Vascular’s Serranator catheter reported high procedural success and wound-healing rates in patients with chronic limb-threatening ischemia, findings that arrive as new reimbursement …
Cagent Study Shows Strong Outcomes in High-Risk Limb Cases Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) recently published results from a Phase 2/3 clinical trial evaluating its investigational drug buntanetap in patients with mild to moderate Alzheimer’s disease, …
Annovis Bio Publishes Phase 2/3 Alzheimer’s Trial Results Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported full results from a Phase 1a clinical trial of its ATI-052 antibody and outlined plans to advance multiple programs, including selecting …
Aclaris Reports Phase 1a Results for ATI-052, Advances Pipeline Read More
WASHINGTON, D.C. — Federal regulators are moving to speed up drug development by launching real-time clinical trials that allow safety data and results to be reviewed as studies are underway …
FDA Pushes Faster Drug Approvals With Real-Time Trials Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will present clinical results from its QTORIN™ rapamycin program at the ISSVA World Congress 2026 in Philadelphia, with data from Phase 3 …
Palvella to Present QTORIN Study Data at ISSVA 2026 Conference Read More